An open single-center, phase I proof of concept trial to assess the safety and feasibility of adoptive cell therapy with autologous EBV-specific cytotoxic T lymphocytes (CTL) in patients with a first clinical episode highly suggestive of multiple sclerosis

2024-515563-55-00 Protocol RC14_0359 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 17 Feb 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol RC14_0359

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 7
Countries 1
Sites 1

Multiple sclerosis

Key facts

Sponsor
Centre Hospitalier Universitaire De Nantes
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
17 Feb 2025 → ongoing
Decision date (initial)
2024-10-03
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-515563-55-00
EudraCT number
2016-000720-26
ClinicalTrials.gov
NCT02912897

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Multiple sclerosis

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Hospitalier Universitaire De Nantes

Sponsor organisation
Centre Hospitalier Universitaire De Nantes
Address
5 Allee De L Ile Gloriette, Cs 69301 Cs 69301
City
Nantes Cedex 1
Postcode
44093
Country
France

Scientific contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
David LAPLAUD

Public contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
David LAPLAUD

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 7 1
Rest of world 0

Investigational sites

France

1 site · Ongoing, recruiting
Centre Hospitalier Universitaire De Nantes
Neurology, Boulevard Du Professeur Jacques Monod, 44800, Saint Herblain

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2021-01-26 2021-01-26

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 1 · Art. 38 CTR

Temporary halt TH-67764

Halt date
2025-01-24
Planned restart
2025-04-07
Member states concerned
France
Publication date
2025-01-24
Reason
Study management related, Sponsor decision
Explanation
Pending authorization to extend the recruitment period
Follow-up measures
There are no ongoing subjects on the trial
Benefit-risk balance changed
No
Treatment stopped
No

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-06 France Acceptable
2024-10-03
2024-10-03
2 SUBSTANTIAL MODIFICATION SM-1 2024-12-19 France Acceptable
2025-02-03
2025-02-12